Medicaid Pharmacy and Therapeutics Committee

New York State Office Of Medicaid Management
Pharmacy and Therapeutics Committee - Agenda for June 9, 2006

The Pharmacy & Therapeutics Committee will meet Friday, June 9, 2006, from 8:45 a.m. to 3:00 p.m., Meeting Room 6, Concourse, Empire State Plaza,Albany, New York

Agenda Items:

1. Identification of preferred drugs in the therapeutic class Leukotriene Modifiers

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: Accolate (zafirlukast), Singulair (montelukast)

2. Identification of preferred drugs in the therapeutic class Hepatitis C Agents

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: PEG-Intron (peginterferon alfa-2b), Pegasys (peginterferon alfa-2a)

3. Identification of preferred drugs in the therapeutic class Thiazolidinediones

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: Actos (pioglitazone), Actoplus met (pioglitazone/metformin), Avandia (rosiglitazone), Avandament (rosiglitazone/metformin), Avandaryl (rosiglitazone/glimepiride)

4. Establishment of procedures for newly approved prescription drugs subject to the Preferred Drug Program

  • Description: The Committee will develop procedures to address newly approved drugs within a therapeutic class subject to the Preferred Drug Program.

5. Transition of the Prescription Proton Pump Inhibitor and Second Generation Antihistamine Programs to the Preferred Drug Program

  • Description: The Committee will discuss the process for transitioning current prior authorization programs to the Preferred Drug Program. This is an administrative transition required by State law. Clinical reviews by the P&TC have been previously completed for these categories. The P&TC will only review new clinical information since the previous reviews (SGAs - January 2003; PPIs - June 2005).

    Drugs Affected:

    Proton Pump Inhibitors: Aciphex (rabeprazole), Nexium (esomeprazole), omeprazole, Prevacid (lansoprazole), Prevacid NapraPAC (lansoprazole/naproxen), Prilosec (omeprazole), Prilosec OTC (omeprazole), Protonix (pantoprazole), Zegerid (omeprazole)

    Second Generation Antihistamines: Allegra/Allegra-D (fexofenadine), Clarinex/Clarinex-D (desloratadine), Claritin/Claritin-D (loratadine), loratadine, fexofenadine, Semprex-D (acrivastine), Zyrtec/Zyrtec-D (cetirizine)

6. Election of Committee Chairperson

AGENDA

8:45 - 9:00  Welcome and Introductions
9:00 - 10:00  Comments from interested parties*
10:00 - 10:45  Clinical Review of Leukotriene Modifiers
10:45 - 11:30  Clinical Review of Hepatitis C Agents
11:30 - 12:00  Clinical Review of Thiazolidinediones (TZDs)
12:00 - 1:00  Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information)
1:00 - 1:10  Final Recommendations for preferred drugs (Leukotriene Modifiers, Hep C Agents and TZDs)
1:10 - 1:40  Review of procedures for newly approved drugs subject to the Preferred Drug Program (PDP)
1:40 - 2:00  Transition of Proton Pump Inhibitor (PPI) and Second Generation Antihistamine (SGA) Prior Authorization Programs to the PDP
2:00 - 2:45  Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information)
2:45 - 2:50  Final Recommendations for SGA and PPI PA Programs Transition Process
2:50 - 2:55   Election of Committee Chairperson
2:55 - 3:00   DOH Update, Final Comments and Adjournment

*Interested parties must notify DOH at least 72 hours in advance of their request to speak at the committee meeting. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit clinical information such as a clinical study, a clinical report, or a clinical executive summary, must submit these documents at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material. If such material is submitted after this time, it cannot be considered by the Committee.

Posted May 10, 2006